Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 12/2013

01-12-2013 | Leading Article

Novel Delivery Systems for Nicotine Replacement Therapy as an Aid to Smoking Cessation and for Harm Reduction: Rationale, and Evidence for Advantages over Existing Systems

Authors: Lion Shahab, Leonie S. Brose, Robert West

Published in: CNS Drugs | Issue 12/2013

Login to get access

Abstract

Nicotine replacement therapy (NRT) has been used in the treatment of tobacco dependence for over three decades. Whilst the choice of NRT was limited early on, in the last ten years there has been substantial increase in the number of nicotine delivery devices that have become available. This article briefly summarises existing forms of NRT, evidence of their efficacy and use, and reviews the rationale for the development of novel products delivering nicotine via buccal, transdermal or pulmonary routes (including nicotine mouth spray, nicotine films, advanced nicotine inhalers and electronic cigarettes). It presents available evidence on the efficacy, tolerability and abuse potential of these products, with a focus on their advantages as well as disadvantages compared with established forms of NRT for use as an aid to both smoking cessation as well as harm reduction.
Literature
1.
Shafey O, Eriksen M, Ross H, Mackay J. The tobacco atlas. 3rd ed. Atlanta: American Cancer Society; 2009.
2.
Waldum HL, Nilsen OG, Nilsen T, Rorvik H, Syversen V, Sanvik AK, et al. Long-term effects of inhaled nicotine. Life Sci. 1996;58:1339–46.PubMed
3.
Sumner W. Estimating the health consequences of replacing cigarettes with nicotine inhalers. Tob Control. 2003;12:124–32.PubMed
4.
Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33:23–9.PubMed
5.
6.
Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron. 1998;21:467–76.PubMed
7.
Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res. 2000;2:19–37.PubMed
8.
Centers for Disease Control and Prevention. The health consequences of smoking: nicotine addiction. A report of the surgeon general. Rockville: US Department of Health and Human Services; 1988.
9.
Royal College of Physicians. Nicotine addiction in Britain. A report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians of London; 2000.
10.
West R. The multiple facets of cigarette addiction and what they mean for encouraging and helping smokers to stop. COPD. 2009;6:277–83.PubMed
11.
International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. In: IARC monographs on the evaluation of carcinogenic risks to humans, vol 83. Lyon: IARC; 2004. p. 973–991.
12.
13.
Johnston L. Tobacco smoking and nicotine. Lancet. 1942;240:742.
14.
Herxheimer A, Griffith R, Hamilton B, Wakefield M. Circulatory effects of nicotine aerosol inhalations and cigarette smoking in man. Lancet. 1967;290:754–5.
15.
Ferno O. Conversation with Ove Ferno. Addiction. 1994;89:1215–26.PubMed
16.
West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med. 2011;365:1193–200.PubMed
17.
Mees HL, Keutzer CS, Lichtenstein E. Modification of smoking behavior: a review. Psychol Bull. 1968;70:520–33.PubMed
18.
Ferno O, Lichtnec SJ, Lundgren CE. Substitute for tobacco smoking. Psychopharmacologia. 1973;31:201–4.PubMed
19.
Brantmark B, Ohlin P, Westling H. Nicotine-containing chewing gum as an anti-smoking aid. Psychopharmacologia. 1973;31:191–200.PubMed
20.
Jarvik M. Conversation with Murray Jarvik. Addiction. 2001;96:1241–52.PubMed
21.
Buchhalter AR, Fant RV, Henningfield JE. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs. 2008;68:1067–88.PubMed
22.
Rose JE, Herskovic JE, Trilling Y, Jarvik ME. Transdermal nicotine reduces cigarette craving and nicotine preference. Clin Pharmacol Ther. 1985;38:450–6.PubMed
23.
Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
24.
Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med. 1999;159:2033–8.PubMed
25.
Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res. 1999;1:169–74.PubMed
26.
Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992;340:324–9.PubMed
27.
Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology (Berl). 1993;111:271–7.
28.
Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. 1995;24:41–7.PubMed
29.
Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66:1253–62.PubMed
30.
Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;CD000146.
31.
Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. Drug Alcohol Rev. 2008;27:529–47.PubMed
32.
Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Report by a subcommittee of the Research Committee of the British Thoracic Society. Br Med J (Clin Res Ed). 1983;286:595–7.
33.
Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002;288:1260–4.PubMed
34.
Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev. 2006;25:59–71.PubMed
35.
Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. Thorax. 1998;53(Suppl 5 Pt 2):S1–38.PubMed
36.
Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6:1–245.
37.
Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet. 1999;354:210–5.PubMed
38.
Akehurst R, Piercy J. Cost-effectiveness of the use of transdermal Nicorette patches relative to GP counselling and nicotine gum in the prevention of smoking related diseases. Br J Med Econ. 1994;7:115–22.
39.
Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997;278:1759–66.PubMed
40.
Appleby J, Devlin N, Parkin D. NICE’s cost effectiveness threshold. BMJ. 2007;335:358–9.PubMed
41.
NICE. Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. In: NICE public health guidance 10. London: National Institute for Health and Clinical Excellence; 2008.
42.
West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000;55:987–99.PubMed
43.
USDHHS. Clinical practical guidelines. In: Treating tobacco use and dependence—2008 update. Rockville: US Department of Health and Human Services P.H.S.; 2008.
44.
Hughes JR, Shiffman S, Callas P, Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control. 2003;12:21–7.PubMed
45.
Raw M, Regan S, Rigotti NA, McNeill A. A survey of tobacco dependence treatment services in 36 countries. Addiction. 2009;104:279–87.PubMed
46.
WHO Tobacco Free Initiative. Policy recommendations for smoking cessation and treatment of tobacco dependence. Geneva: WHO; 2003.
47.
Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology (Berl). 1984;83:82–7.
48.
West R, Jarvis MJ, Russell MA, Carruthers ME, Feyerabend C. Effect of nicotine replacement on the cigarette withdrawal syndrome. Br J Addict. 1984;79:215–9.PubMed
49.
Jarvis MJ, Raw M, Russell MA, Feyerabend C. Randomised controlled trial of nicotine chewing-gum. Br Med J (Clin Res Ed). 1982;285:537–40.
50.
West R. The ‘nicotine replacement paradox’ in smoking cessation: how does nicotine gum really work? Br J Addict. 1992;87:165–7.PubMed
51.
Shiffman S, Fant RV, Buchhalter AR, Gitchell JG, Henningfield JE. Nicotine delivery systems. Expert Opin Drug Deliv. 2005;2:563–77.PubMed
52.
Esterlis I, Mitsis EM, Batis JC, Bois F, Picciotto MR, Stiklus SM, et al. Brain beta2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol. 2011;14:389–98.PubMed
53.
West R, Shiffman S. Fast facts: smoking cessation. 2nd ed. Oxford: Health Press; 2007.
54.
Beard E, McNeill A, Aveyard P, Fidler J, Michie S, West R. Association between use of nicotine replacement therapy for harm reduction and smoking cessation: a prospective study of English smokers. Tob Control. 2013;22:118–22.PubMed
55.
Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;338:b1024.PubMed
56.
Agboola S, McNeill A, Coleman T, Leonardi BJ. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction. 2010;105:1362–80.PubMed
57.
Raw M, McNeill A, West R, Arnott D. Guidance for health professionals on changes in the licensing arrangements for nicotine replacement therapy. London: ASH; 2005.
58.
Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J. 1998;53(suppl):75–114.PubMed
59.
Schneider NG, Koury MA, Cortner C, Olmstead RE, Hartman N, Kleinman L, et al. Preferences among four combination nicotine treatments. Psychopharmacology (Berl). 2006;187:476–85.
60.
Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med. 2004;140:426–33.PubMed
61.
West R, DiMarino ME, Gitchell J, McNeill A. Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control. 2005;14:166–71.PubMed
62.
Kotz D, Fidler JA, West R. Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? Nicotine Tob Res. 2011;13:793–9.PubMed
63.
Pomerleau OF. Nicotine and the central nervous system: biobehavioral effects of cigarette smoking. Am J Med. 1992;93:2S–7S.PubMed
64.
Russell MA, Sutton SR, Iyer R, Feyerabend C, Vesey CJ. Long-term switching to low-tar low-nicotine cigarettes. Br J Addict. 1982;77:145–58.PubMed
65.
McRobbie H, Raw M, Chan S. Research priorities for Article 14—demand reduction measures concerning tobacco dependence and cessation. Nicotine Tob Res. 2013;15:805–16.PubMed
66.
DeVeaugh-Geiss AM, Chen LH, Kotler ML, Ramsay LR, Durcan MJ. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. Clin Ther. 2010;32:1140–8.PubMed
67.
Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology (Berl). 2006;184:637–44.
68.
Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999;13:238–46.PubMed
69.
Chen L-L, Inventors. United States Patent Application Publication (US 20011/0110880 A1). Nicotine Lozenge compositions (Application number: 12/990,049, filed 30 Apr 2009). 2011.
70.
71.
Shahab L, McEwen A, West R. Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial. Psychopharmacology (Berl). 2011;216:187–96.
72.
Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, et al. Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction. 2005;100:1720–30.PubMed
73.
Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, et al. Rapid absorption of nicotine from new nicotine gum formulations. Pharmacol Biochem Behav. 2009;91:380–4.PubMed
74.
McEwen A, West R, Gaiger M. Nicotine absorption from seven current nicotine replacement products and a new wide-bore nicotine delivery device. J Smok Cessat. 2008;3:117–23.
75.
Bolliger CT, van Biljon X, Axelsson A. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy. Respiration. 2007;74:196–201.PubMed
76.
Kraiczi H, Hansson A, Perfekt R. Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. Nicotine Tob Res. 2011;13:1176–82.PubMed
77.
McRobbie H, Thornley S, Bullen C, Lin RB, Senior H, Laugesen M, et al. A randomized trial of the effects of two novel nicotine replacement therapies on tobacco withdrawal symptoms and user satisfaction. Addiction. 2010;105:1290–8.PubMed
78.
Hansson A, Hajek P, Perfekt R, Kraiczi H. Effects of nicotine mouth spray on urges to smoke, a randomised clinical trial. BMJ Open. 2012;2:e001618.
79.
Tonnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J. 2012;40:548–54.PubMed
80.
Thornley S, McRobbie H, Lin RB, Bullen C, Hajek P, Laugesen M, et al. A single-blind, randomized, crossover trial of the effects of a nicotine pouch on the relief of tobacco withdrawal symptoms and user satisfaction. Nicotine Tob Res. 2009;11:715–21.PubMed
81.
Walker N, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, et al. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction. 2011;106:1176–85.PubMed
82.
Caldwell B, Burgess C, Crane J. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nicotine Tob Res. 2010;12:179–83.PubMed
83.
84.
Cilurzo F, Cupone IE, Minghetti P, Buratti S, Selmin F, Gennari CG, et al. Nicotine fast dissolving films made of maltodextrins: a feasibility study. AAPS PharmSciTech. 2010;11:1511–7.PubMed
85.
86.
Valenta C, Auner BG. The use of polymers for dermal and transdermal delivery. Eur J Pharm Biopharm. 2004;58:279–89.PubMed
87.
Pichayakorn W, Suksaeree J, Boonme P, Amnuaikit T, Taweepreda W, Ritthidej GC. Deproteinized natural rubber film forming polymeric solutions for nicotine transdermal delivery. Pharm Dev Technol. 2013;18:1111–21.PubMed
88.
Rao S, Song Y, Peddie F, Evans AM. A novel tri-layered buccal mucoadhesive patch for drug delivery: assessment of nicotine delivery. J Pharm Pharmacol. 2011;63:794–9.PubMed
89.
Strasinger CL, Scheff NN, Wu J, Hinds BJ, Stinchcomb AL. Carbon nanotube membranes for use in the transdermal treatment of nicotine addiction and opioid withdrawal symptoms. Subst Abuse. 2009;3:31–9.PubMed
90.
Paudel KS, Wu J, Hinds BJ, Stinchcomb AL. Programmable transdermal delivery of nicotine in hairless guinea pigs using carbon nanotube membrane pumps. J Pharm Sci. 2012;101:3823–32.PubMed
91.
Wu J, Paudel KS, Strasinger C, Hammell D, Stinchcomb AL, Hinds BJ. Programmable transdermal drug delivery of nicotine using carbon nanotube membranes. Proc Natl Acad Sci USA. 2010;107:11698–702.PubMed
92.
D’Orlando KJ, Fox BS. Tolerability and pharmacokinetics of single and repeated doses of nicotine with the straw, a novel nicotine replacement product. Nicotine Tob Res. 2004;6:63–70.PubMed
93.
Westman EC, Tomlin KF, Perkins CE, Rose JE. Oral nicotine solution for smoking cessation: a pilot tolerability study. Nicotine Tob Res. 2001;3:391–6.PubMed
94.
Henningfield JE, Radzius A, Cooper TM, Clayton RR. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA. 1990;264:1560–4.PubMed
95.
Islam N, Rahman S. Improved treatment of nicotine addiction and emerging pulmonary drug delivery. Drug Discov Ther. 2012;6:123–32.PubMed
96.
Caldwell B, Sumner W, Crane J. A systematic review of nicotine by inhalation: is there a role for the inhaled route? Nicotine Tob Res. 2012;14:1127–39.PubMed
97.
Lux JE, Frecker RC. Subjective responses to inhaled and intravenous injected nicotine. Clin Pharmacol Ther. 1988;43:186.
98.
Burch SG, Erbland ML, Gann LP, Hiller FC. Plasma nicotine levels after inhalation of aerosolized nicotine. Am Rev Respir Dis. 1989;140:955–7.PubMed
99.
Andrus PG, Rhem R, Rosenfeld J, Dolovich MB. Nicotine microaerosol inhaler. Can Respir J. 1999;6:509–12.PubMed
100.
Caldwell B, Dickson S, Burgess C, Siebers R, Mala S, Parkes A, et al. A pilot study of nicotine delivery to smokers from a metered-dose inhaler. Nicotine Tob Res. 2009;11:342–7.PubMed
101.
Farr SJ, Warren SJ, Lloyd P, Okikawa JK, Schuster JA, Rowe AM, et al. Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. Int J Pharm. 2000;198:63–70.PubMed
102.
Rose JE, Turner JE, Murugesan T, Behm FM, Laugesen M. Pulmonary delivery of nicotine pyruvate: sensory and pharmacokinetic characteristics. Exp Clin Psychopharmacol. 2010;18:385–94.PubMed
103.
Wollscheid KA, Kremzner ME. Electronic cigarettes: safety concerns and regulatory issues. Am J Health Syst Pharm. 2009;66:1740–2.PubMed
104.
Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L. Nicotine levels in electronic cigarettes. Nicotine Tob Res. 2013;15:158–66.PubMed
105.
Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control. 2010;19:98–103.PubMed
106.
Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev. 2010;19:1945–53.PubMed
107.
Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res. 2013;15:267–70.PubMed
108.
Dawkins L, Turner J, Hasna S, Soar K. The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. Addict Behav. 2012;37:970–3.PubMed
109.
Bullen C, Williman J, Howe C, Laugesen M, McRobbie H, Parag V, et al. Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation. BMC Public Health. 2013;13:210.PubMed
110.
Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. Efficiency and safety of an electronic cigarette (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013;8:e66317.PubMed
111.
Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet (In press).
112.
Polosa R, Morjaria JB, Caponnetto P, Campagna D, Russo C, Alamo A, et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Intern Emerg Med. 2013. doi:10.​1007/​s11739-013-0977-z.
113.
Caponnetto P, Auditore R, Russo C, Cappello GC, Polosa R. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health. 2013;10:446–61.PubMed
114.
Trehy ML, Ye W, Hadwiger ME, Moore TW, Allgire JF, Woodruff JT, et al. Analysis of electronic cigarette cartridges, refill solutions, and smoke for nicotine and nicotine related impurities. J Liquid Chromatogr Relat Technol. 2011;34:1442–58.
115.
Hajek P. Withdrawal-oriented therapy for smokers. Br J Addict. 1989;84:591–8.PubMed
116.
Hurt RD, Dale LC, McClain FL, Eberman KM, Offord KP, Bruce BK, et al. A comprehensive model for the treatment of nicotine dependence in a medical setting. Med Clin North Am. 1992;76:495–514.PubMed
117.
Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012;10:CD008286.
118.
Sutherland G. Evidence for counselling effectiveness for smoking cessation. J Clin Psychiatry Monogr. 2003;18:22–34.
119.
Shahab L, Fidler J. Tobacco-related disorders. In: Sturmey P, Hersen M, editors. Handbook of evidence-based practice in clinical psychology: adult disorders, vol. II. New York: Wiley; 2012. pp. 167–96.
120.
McEwen A, Hajek P, McRobbie H, West R. Manual of smoking cessation. Oxford: Blackwell Publishing; 2006.
121.
Shahab L. Cost-effectiveness of pharmacotherapy for smoking cessation (NCSCT Briefing: 7). In: McEwen A, editor. NHS Centre for Smoking Cessation and Training Briefings. London: NCSCT; 2011.
122.
Fidler JA, Shahab L, West O, Jarvis MJ, McEwen A, Stapleton JA, et al. ‘The smoking toolkit study’: a national study of smoking and smoking cessation in England. BMC Public Health. 2011;11:479.PubMed
Metadata
Title
Novel Delivery Systems for Nicotine Replacement Therapy as an Aid to Smoking Cessation and for Harm Reduction: Rationale, and Evidence for Advantages over Existing Systems
Authors
Lion Shahab
Leonie S. Brose
Robert West
Publication date
01-12-2013
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 12/2013
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-013-0116-4

Other articles of this Issue 12/2013

CNS Drugs 12/2013 Go to the issue

Review Article

Clinically Significant Drug Interactions with Atypical Antipsychotics

Review Article

Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor

Original Research Article

Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study

Erratum

Erratum to: Systematic Review and Meta-Analysis of the Efficacy and Safety of Perampanel in the Treatment of Partial-Onset Epilepsy

Review Article

Animal Migraine Models for Drug Development: Status and Future Perspectives

Acknowledgement to Referees

Acknowledgement